With $6.5M in new funding, the Israeli bioinformatics startup is looking to open a US office as it builds relationships with pharma, cancer centers, and payors.
The analysis suggested survival and other benefits for breast cancer patients with BRCA1/2 mutations who were aware of their germline risk before diagnosis.
The initial investment is led by Debiopharm, which will collaborate with the Israeli startup to accelerate discovery of biomarkers for oncology drug response.
